Edition:
United States

Urogen Pharma Ltd (URGN.OQ)

URGN.OQ on NASDAQ Stock Exchange Global Market

50.00USD
20 Feb 2018
Change (% chg)

$2.08 (+4.34%)
Prev Close
$47.92
Open
$48.54
Day's High
$50.22
Day's Low
$47.07
Volume
115,882
Avg. Vol
49,625
52-wk High
$56.43
52-wk Low
$13.01

Chart for

About

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for... (more)

Overall

Beta: --
Market Cap(Mil.): $760.74
Shares Outstanding(Mil.): 15.21
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 180.40 17.28
EPS (TTM): -- -- --
ROI: -- -0.52 35.61
ROE: -- -3.30 17.17

BRIEF-Urogen Pharma Announces Pricing Of Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PRICING OF PUBLIC OFFERING OF ORDINARY SHARES

Jan 18 2018

BRIEF-Urogen Announces Proposed Public Offering Of Ordinary Shares

* UROGEN PHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

Jan 16 2018

BRIEF-Urogen Pharma Q3 loss per share $0.02

* Urogen Pharma reports third quarter 2017 financial results and recent corporate developments

Nov 14 2017

BRIEF-Menora Mivtachim reports 5.38 pct passive stake in UroGen Pharma ‍​

* Menora Mivtachim Holdings Ltd reports 5.38 percent passive stake in UroGen Pharma Ltd as of Nov 1 - SEC filing ‍​ Source: (http://bit.ly/2hdmj4k) Further company coverage:

Nov 08 2017

BRIEF-Urogen Pharma receives FDA fast track designation for Mitogel

* Urogen Pharma receives FDA fast track designation for Mitogel for the treatment of upper tract urothelial carcinoma (UTUC)

Aug 29 2017

Earnings vs. Estimates